Site Search
Displaying results 31 - 40 of 345
Resource | Publications,
The WHO South-East Region in 2019 accounted for nearly a million missing TB patients from the estimated incidence. Active case-finding (ACF) or systematic screening for tuberculosis is an important tool to reach out to missing TB patients. When appropriately implemented, the activity is cost effective, helps to reduce diagnosis and treatment delays, and prevents the spread of the disease. This document presents an analysis of published ACF studies from the Region. It can be used by Member States for effective planning, implementation and monitoring of these activities.
Resource | Presentations,
Browse and view tables, charts and graphs illustrating data on key populations, HIV prevalence and epidemiology, risk behaviors, gender-based violence, HIV knowledge, HIV expenditures, country responses, and treatment.
Resource | Publications,
In an effort to foster and achieve universal access to TB diagnostics and inform research and development (R&D) priorities for TB diagnostic tools, the World Health Organization (WHO) has released an updated target product profile (TPP) for next-generation tuberculosis drug-susceptibility (DST) testing for M. tuberculosis at peripheral centres.
This is an update of one of the high-priority TPPs published by WHO for new TB diagnostics in light of several advances in the TB diagnostics and treatment pipelines that have been observed. This updated TPP is intended to specify desire attributes of next-generation drug-susceptibility testing for M. tuberculosis and align the development of new interventions with evolving gaps and the needs of individuals and populations.
Resource | Publications,
WHO’s Global Tuberculosis (TB) Programme has published a book that provides a global synthesis of results and lessons learned from national TB prevalence surveys implemented 2007-2016. This was a collaborative effort of 24 countries and their technical partners with contributions from more than 450 people.
Resource | Publications,
The aim of this document is to assist national tuberculosis (TB) programmes in developing the strongest possible mechanisms of surveillance for drug resistance in TB, building on more than 25 years of global experience. This starts from periodic surveys of sampled patients, moving towards an ultimate goal of continuous surveillance systems based on routine drug susceptibility testing (DST). This guidance promotes certain standardized criteria for surveillance to ensure that results are comparable within and between countries over time. The target audience of this document is national TB programmes and, in particular, the coordination team for surveillance ideally composed of the programme manager, a laboratory specialist, a logistician, and an epidemiologist/statistician.
Resource | Publications,
This document summarizes current evidence on TB outbreaks in schools and contextualizes the information within the Western Pacific Region. Case studies from four countries highlighted the diverse range of experiences in the Region. As many countries have minimal experience in preventing and responding to TB outbreaks in schools, evidence from past outbreaks and case studies from a few countries could inform future responses.
Resource | Publications,
A situational assessment is an important step in national adaptation of a global strategy. Ideally, it is conducted as part of the planning cycle in implementation of the strategy and updated every few years. The checklist presented here is designed to support countries in planning their analyses according to their own contexts. While it sets out the key principles and recommendations to frame the situational assessment, it deliberately avoids being overly prescriptive, giving countries the space and flexibility to determine what is missing, what should be strengthened and the most feasible approaches to addressing pressing challenges. It consists of four topics aligned with the four objectives of the strategy to strengthen thematic analyses.
This tool is not designed for identifying or prioritizing research gaps but rather for improving policy and strategic decisions to enhance TB research on the four thematic areas (objectives) of the global strategy. For those interested in developing a research agenda, WHO has published a toolkit that provides guidance and allows sharing of best practices.
Resource | Publications,
The past two decades have seen unprecedented progress in fighting HIV, TB and malaria, although a further acceleration is required to achieve national and global goals. Progress has been uneven across regions, population groups and interventions. Achieving the ambitious goals of the Sustainable Development Agenda requires leveraging lessons learned and scientific progress, including efforts to scale up cost-effective approaches that reach key populations through wider primary health care (PHC) and health systems strengthening strategies, and ensuring adequate levels of domestic funding, complemented, where required, by development partner support.
Resource | Publications,
Tuberculosis (TB) prevention is essential for reaching the End TB targets in the South-East Asia Region (SEAR) of World Health Organization (WHO). The targets of 80% reduction in TB incidence rate and 90% reduction in TB mortality by 2030 (compared to 2015 levels) can be achieved only with additional interventions aimed at preventing TB, according to epidemiological modelling studies commissioned by the WHO South-East Asia Regional Office (WHO SEARO). Optimal implementation of TB preventive treatment (TPT) is a critical intervention to accelerate reduction in TB burden in the SEA Region, which bears nearly 43% of the global TB burden. TPT by itself has the potential to reduce the overall annual TB incidence rates by 8.3% (95% CrI 6.5–10.8) relative to 2015.
Resource | Publications,
For the second year, global funding for tuberculosis (TB) research and development (R&D) surpassed US$900 million—this time, just barely, with US$900,964,590 spent on TB R&D in 2019. An optimist would emphasize that this figure represents the second highest level of funding for TB research ever recorded by Treatment Action Group (TAG) and the Stop TB Partnership. A realist would point out that funding for TB R&D continues to fall more than halfway short of the US$2 billion per year called for in the political declaration of the 2018 United Nations High-Level Meeting on TB (UN HLM).